These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16883012)

  • 1. Response-dependent differences in regional cerebral blood flow changes with citalopram in treatment of major depression.
    Joe AY; Tielmann T; Bucerius J; Reinhardt MJ; Palmedo H; Maier W; Biersack HJ; Zobel A
    J Nucl Med; 2006 Aug; 47(8):1319-25. PubMed ID: 16883012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression.
    Brockmann H; Zobel A; Joe A; Biermann K; Scheef L; Schuhmacher A; von Widdern O; Metten M; Biersack HJ; Maier W; Boecker H
    Psychiatry Res; 2009 Aug; 173(2):107-12. PubMed ID: 19540732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders.
    Cho SC; Hwang JW; Kim BN; Lee HY; Kim HW; Lee JS; Shin MS; Lee DS
    J Psychiatr Res; 2007 Sep; 41(6):459-65. PubMed ID: 16839567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment anterior cingulate activity as a predictor of antidepressant response to repetitive transcranial magnetic stimulation (rTMS).
    Langguth B; Wiegand R; Kharraz A; Landgrebe M; Marienhagen J; Frick U; Hajak G; Eichhammer P
    Neuro Endocrinol Lett; 2007 Oct; 28(5):633-8. PubMed ID: 17984932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
    Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
    Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment.
    Pålhagen SE; Ekberg S; Wålinder J; Granérus AK; Granerus G
    J Neurol; 2009 Sep; 256(9):1510-8. PubMed ID: 19430931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of treatment response in major depression: integration of concepts.
    Mulert C; Juckel G; Brunnmeier M; Karch S; Leicht G; Mergl R; Möller HJ; Hegerl U; Pogarell O
    J Affect Disord; 2007 Mar; 98(3):215-25. PubMed ID: 16996140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
    Choi MJ; Kang RH; Lim SW; Oh KS; Lee MS
    Brain Res; 2006 Nov; 1118(1):176-82. PubMed ID: 16979146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression.
    Linka T; Müller BW; Bender S; Sartory G
    Neurosci Lett; 2004 Sep; 367(3):375-8. PubMed ID: 15337269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-HMPAO SPECT study of cerebral perfusion after treatment with medication and electroconvulsive therapy in major depression.
    Kohn Y; Freedman N; Lester H; Krausz Y; Chisin R; Lerer B; Bonne O
    J Nucl Med; 2007 Aug; 48(8):1273-8. PubMed ID: 17631560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes of day-time and night-time gross motor activity in clinical responders and non-responders of major depression.
    Todder D; Caliskan S; Baune BT
    World J Biol Psychiatry; 2009; 10(4):276-84. PubMed ID: 19921969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD; Shults J; Rutherford N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regional cerebral blood flow changes in schizophrenic patients detected by SPECT studies under resting and active conditions].
    Ambrus E; Szekeres G; Kéri S; Csernay L; Janka Z; Pávics L
    Orv Hetil; 1999 Aug; 140(32):1783-6. PubMed ID: 10489761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal mood variation in outpatients with major depressive disorder.
    Morris DW; Trivedi MH; Fava M; Wisniewski SR; Balasubramani GK; Khan AY; Jain S; Rush AJ
    Depress Anxiety; 2009; 26(9):851-63. PubMed ID: 19306304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.